Travere Therapeutics (TVTX) Stock Price, Quote, News & History | Benzinga

Travere Therapeutics Inc (TVTX) Stock Price, Quote, News & History

TVTXNASDAQ

Trade with Public

Trade with Public

$42.96

-2.08-4.62%

At close: Jun 1, 5:00 PM EST

$44.09

-0.95-2.11%

Pre-Market: 4:01 AM EST

OverviewNews Earnings Events Options Guidance Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

-

Close

$42.96

Volume / Avg.

5.00 / 2.14M

Day Range

- - -

52 Wk Range

13.88 - 48.61

Market Cap

$4.10B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

19.7%

Days to Cover

4.48

Recent Travere Therapeutics Inc News

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fell 1.1% on Tuesday, analysts have raised price targets.

Avi Kapoor

FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients

Travere says FILSPARI gains full FDA approval for FSGS, expanding treatment scope and showing strong proteinuria reduction in trials.

Vandana Singh

Travere Stock Slips After FDA Delays Review Of Key Kidney Drug

Travere Therapeutics' stock declines as FDA extends review of key kidney drug. Q4 sales forecast at $127 million.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

39.61M

Investing Cash Flow (TTM)

8.15M

Financing Cash Flow (TTM)

-32.98M

Free Cash Flow (TTM)

-28.94M

Capital Expenditure (TTM)

-68.55M

Net Change in Cash (TTM)

14.78M

Analyst Trends and Forecast

1

Feb

1

Mar

6

Apr

5

May

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$4.25B

PE Ratio (TTM)

-

PE Ratio (FWD)

58.82

PEG Ratio (TTM)

-

PS Ratio (TTM)

7.22

PB Ratio (TTM)

40.46

Earnings Yield % (TTM)

-1.16%

Earnings Yield % (FWD)

1.70%

EV / EBITDA (TTM)

105.30

Price / EBITDA (TTM)

100.43

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.06

Company Debt

Total Debt

$312.08M

LT Debt

$312.08M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$78.36M

Debt to Equity

3.32

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$42.96

Volume / Avg.

5.00 / 2.14M

Day Range

- - -

52 Wk Range

13.88 - 48.61

Market Cap

$4.10B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

19.7%

Days to Cover

4.48

About

Sector

Health Care

Industry

Biotechnology

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Travere Therapeutics (TVTX) stock?

A

You can purchase shares of Travere Therapeutics (NASDAQ:TVTX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Travere Therapeutics (TVTX) competitors?

A

There are no as such competitors for Travere Therapeutics.

Q

What is the forecast, or price target, for Travere Therapeutics (TVTX) stock?

A

Travere Therapeutics has a consensus price target of $40.74.

Q

What is the current price for Travere Therapeutics (TVTX)?

A

The stock price for Travere Therapeutics (NASDAQ: TVTX) is $44.09 last updated June 2, 2026 at 4:10 PM EDT.

Q

Does Travere Therapeutics (TVTX) pay a dividend?

A

There are no upcoming dividends for Travere Therapeutics.

Q

When is Travere Therapeutics (NASDAQ:TVTX) reporting earnings?

A

Travere Therapeutics does not have any upcoming earnings scheduled.

Q

Is Travere Therapeutics (TVTX) going to split?

A

There is no upcoming split for Travere Therapeutics.

Q

What sector and industry does Travere Therapeutics (TVTX) operate in?

A

Travere Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.